Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study

Published:2015-11-05 Issue:2 Volume:172 Page:262-273
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Newland Adrian¹,Godeau Bertrand²,Priego Victor³,Viallard Jean-Francois⁴,López Fernández María F.⁵,Orejudos Amelia⁶,Eisen Melissa⁷

Affiliation:

1. The Pathology Clinical Academic Group; Pathology Clinical Academic Unit, Pathology and Pharmacy Building; The Royal London Hospital; London UK

2. Department of Internal Medicine; Centre Hospitalier Universitaire (CHU) Henri-Mondor; INSERM U955; Créteil Cedex France

3. The Center for Cancer and Blood Disorders; Bethesda MD USA

4. Universite Victor Segalen Bordeaux; Pessac Cedex France

5. C.Hospitalario Universitario A Coruña-INIBIC; Laboratorio de Hematología,Carretera de las Jubias; Galicia Spain

6. Amgen Inc.; Morganville NJ USA

7. Amgen Inc.; Thousand Oaks CA USA

Funder

Amgen

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13827/fullpdf

Reference36 articles.

1. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura;Arnold;Annals of Internal Medicine,2007

2. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents;Bao;Blood,2010

3. Low doses v conventional doses of corticoids in immune thrombocytopenic purpura (ITP): results of a randomized clinical trial in 160 children, 223 adults;Bellucci;Blood,1988

4. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults;Borst;Annals of Hematology,2004

5. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP;Bussel;Blood,2009

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Immune Thrombocytopenia Treatment Landscape: A Focus on Patient Perspectives and Unmet Clinical Needs;EMJ Hematology;2024-09-11

2. Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment;Blood Reviews;2024-09

3. Tapering and Sustained Remission of Thrombopoietin Receptor Agonists (TPO-RAs): Is it Time for Paediatric ITP?;Advances in Therapy;2024-08-20

4. Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway;British Journal of Haematology;2024-08-05

5. Platelet-derived TGF-β1 induces functional reprogramming of myeloid-derived suppressor cells in immune thrombocytopenia;Blood;2024-07-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3